Feedback
If you have any needs please leave us a message
Contact Us
86-0755-82783379
[ Online 8:30-17:30 ]

Industry dynamic

Location:Home > NEWS CENTER > Industry dynamic

The real situation of 3D printing in personalized medicine industry

Date:2016-09-05 Hits:388
The real situation of 3D printing in personalized medicine industry


How should do customization shaping? How to achieve the perfect plastic? Over the years, personal and perfect words to use to promotion, but perfect personalized in the true sense is not easy. However, as medical 3D printing technology matures, the perfect plastic seems to have close at hand. Recently, multiple messages focus 3D printing plastic technology, so that the industry startled.


    3D printing actively promote organ transplantation

    For the future of 3D printing, it has been full of expectations. Scientists have been studying its clinical application in organ transplantation and in terms of shaping potential. Recently, the Anglo-American countries have made big progress. According to media reports, recently, the United States Wake Forest Baptist Medical Center in regenerative medicine scientists have confirmed that the use of a complex, custom designed 3d printer, you can print the structure of living tissue implanted in a patient, replace injured or diseased tissue. The study appears in the February 15 "NatureBiotechnology", the scientists say they use this 3d printer to print the ears, bone and muscle structure. When these structures are implanted in animals, they will grow into a functional organization, and develop vascular system. Most importantly, these early results suggest that these structures have an appropriate size, strength, and function, can be used in humans.

    At the same time, through Morris Wales Hospital plastic surgeon who also actively developing new 3D printing and related method, which aims to help patients use their cell-based cartilage 3D printing biological body organs, such as the nose and ears . They want to be able to this method for the first human clinical trials within the next three to four years.